i.
Director of Digital Innovation at Seuss+, a life sciences consultancy founded in 2012 in Amsterdam.
01 · Regulatory landscape
Where the bar sitsICH GCP E6(R3) · EMA · FDA 21 CFR Part 11
About Lauren Alani
Strategic systems governance, navigating innovation in clinical development.
Director of Digital Innovation at Seuss+, working at the layer where sponsor intent meets vendor execution. More than fifteen years in life sciences. Over seven years in clinical technology. Chair of the ACDM eDigital Data Management Expert Group, 2019-2024.
At a glance
Who Lauren is, quickly.
ii.
15+ years in life sciences, 7+ years in clinical technology across uMotif, Cytel, Novadiscovery, and Seuss+.
iii.
Chair of the ACDM eDigital Data Management Expert Group, 2019-2024. Co-author of four ACDM industry whitepapers. Ongoing collaborator with the Digital Medicine Society.
iv.
RQA-certified in Computerised System Validation. ICH GCP E6 (R2) certified. UK-based. Works with sponsors globally.
The accountability discipline
What I write and speak about
Innovation is welcome. Only when it is validated.
The work sits at the layer where sponsor intent meets vendor execution. That is where the data lives. That is where regulatory expectations are accelerating. And that is where, in my experience, most of the risk accumulates quietly, until an inspector, a board, or an investor starts asking pointed questions.
The sponsor signed the protocol. The sponsor owns the data. No master service agreement transfers that. Compliance is not an obstacle to innovation; it is the architecture that protects asset value, investor confidence, and long-term clinical success.
Foundational belief, refined across sponsor engagements 2019-2024. Continue reading the four core topics below.
The data behind the perspectives
Regulatory anchors and inspection patterns.
Every Lauren perspective is grounded against a vetted data point. The five below are the recurring evidence base across her four topics.
- EMA GCP Inspectors Working Group, 2023 Computer systems generated 46 inspection findings: 5 critical, 22 major. Sponsors received the highest number of critical findings in all three top areas.
- FDA Form 483 analysis, 2014-2018 Roughly 50% of all global drug Form 483s cite data integrity concerns; 79% of warning letters reference data integrity issues. (Govzilla)
- FDA inspections, 2018-2024 Of 194 domestic drug manufacturing inspections, findings made in 138; data integrity issues found in 81 of those 138. (GMP Platform)
- ACRP global site survey, 2024 Across approximately 850 sites, 19% cited sponsor-provided technology as a top operational challenge. (ACRP, October 2024)
- ICH GCP E6(R3) §10.1-10.3, §3.6.7, §4.10 The sponsor may transfer or delegate tasks but retains overall responsibility, including for the quality and integrity of trial data, validation oversight, and service-provider suitability assessment.
About
I am the Director of Digital Innovation at Seuss+, a life sciences consultancy supporting biotechnology and pharmaceutical sponsors across clinical development. The work sits at the layer where sponsor intent meets vendor execution, helping sponsors see across the full trial architecture rather than within a single function’s silo.
My career began in life sciences with Quintiles in 2009. The last seven of those years have been in clinical technology specifically: electronic data capture and patient engagement platforms at uMotif, biostatistics SaaS at Cytel, modelling and simulation at Novadiscovery, and now clinical systems governance at Seuss+. The throughline has been the same question across every role: how does the data move, who is accountable for it at each handoff, and what evidence demonstrates that accountability under regulatory inspection?
What I do
The day-to-day work spans clinical systems analysis, computerised system validation aligned with ICH GCP E6(R3), EMA guidelines, and FDA 21 CFR Part 11; vendor qualification and ongoing oversight; risk-based governance across the trial lifecycle; and sponsor accountability frameworks. The ecosystem perspective is the throughline: no single party (sponsor, CRO, or vendor) currently owns the full data journey, yet the sponsor remains accountable for it.
The four core topics on this site articulate where I see the structural gaps and what sponsors can do about them. Accountability cannot be delegated. The regulator-vendor gap exists by design, not accident. Requirements precede selection, not the other way round. And data integrity is not regulatory hygiene; it is enterprise risk that touches asset valuation directly.
Beyond Seuss+
I chaired the ACDM eDigital Data Management Expert Group from 2019 to 2024 and co-authored four industry whitepapers in that period. I continue to collaborate with the Digital Medicine Society on programmes that translate regulatory expectation into operational reality for sponsors. I served as Regional Director for Market Research at the Healthcare Businesswomen’s Association from 2019 to 2024, including a stint as Operational Director earlier in that tenure.
I speak regularly at industry events, on podcasts, and at sponsor-side roundtables on clinical systems governance, sponsor accountability, and the evolving regulatory environment. ARKFest 2026 is a confirmed return engagement.
Working style
I am UK-based and work with sponsors globally. Engagements tend to involve clinical operations leadership, heads of data management and quality, CTOs at biotech, and increasingly, investors conducting due diligence on clinical-stage assets. The work is diplomatic before it is confrontational. The questioning approach used through these pages is not a style choice; it is the rhetorical structure for exposing assumptions without combativeness.
I hold a BSc (Hons) in Medical Microbiology and Immunology from Newcastle University, am RQA-certified in Computerised System Validation, ICH GCP E6 (R2) certified, and completed Cambridge University’s “Communication for Influence and Impact” programme.
Perspectives
Four topics keep showing up.
Across the sponsor engagements I have watched succeed, struggle, or surface problems late, the same four structural patterns repeat. These are the perspectives that anchor my writing, my speaking, and my advisory work.
i.
Accountability Cannot Be Delegated
You can delegate tasks. You cannot delegate responsibility. The MSA does not transfer the regulatory burden.
Sponsors enter master service agreements assuming that vendor-supplied “validated” systems and CRO-led trial conduct discharge their accountability. They do not. Regulators continue to hold the sponsor accountable for the full data lifecycle, regardless of who built the system or who runs the trial. Activity is frequently mistaken for accountability, and the gap surfaces only when an inspection arrives or a submission is questioned.
Accountability is retained, even when execution is delegated. It must be actively structured, revisited, and evidenced throughout the trial. Governance should be framed as enabling clarity, not slowing progress. “We assumed the vendor had handled it” is almost never a defensible position; it is a signal that ownership of the data was never explicitly assigned.
Takeaways
- Contracts transfer work. They do not transfer regulatory accountability.
- Sponsor oversight must be evidenced, not assumed. Documentation is the proof.
- “Vendor said it was validated” is not a defence under inspection.
ii.
The Regulator-Vendor Gap
Regulators set expectations vendors are not directly accountable for. Sponsors absorb the gap by default.
Regulatory expectations under ICH GCP E6(R3), EMA guidelines, and FDA 21 CFR Part 11 apply to the sponsor. Vendors operate within whatever contractual specifications a sponsor sets, but they are not directly accountable to the regulator for the trial’s compliance posture. That gap is structural, and sponsors absorb it whether or not they recognise it as a gap.
Closing the gap means translating regulatory expectations into vendor-facing requirements before contracts are signed, not after. It means building qualification and oversight processes that produce evidence the sponsor can present to an inspector, in the sponsor’s own voice, with the sponsor’s own documentation. Vendor assurances are necessary but never sufficient.
Takeaways
- The regulator-vendor gap is structural, not accidental.
- Translation of regulatory expectation into vendor specifications is the sponsor’s job.
- Inspection-ready evidence has to live in the sponsor’s records, not the vendor’s.
iii.
Requirements Before Selection
Define trial-level requirements before selecting clinical technology. Selection without specification is a procurement risk.
Sponsors routinely select clinical systems (EDC, eCOA, ePRO, IRT, wearables) based on vendor demos, peer recommendations, or commercial relationships, then attempt to map their trial requirements into the chosen platform after the fact. The sequence is reversed. Trial-level requirements (data flows, regulatory anchors, integration touchpoints, oversight needs) should drive the selection. Anything else is procurement risk dressed up as efficiency.
Requirements-led selection takes longer up front. It also produces fewer mid-trial system changes, fewer oversight blind spots, and a stronger position when validation evidence is later requested. The cost of getting the sequence wrong tends to compound silently, then surface at the worst possible moment.
Takeaways
- Define requirements before selecting clinical technology, not after.
- Vendor demos optimise for the vendor’s strengths, not your trial’s needs.
- Time spent on requirements compounds in your favour. Time saved by skipping them does not.
iv.
Data Integrity Is a Commercial Risk
Compliance protects asset value, investor confidence, and long-term clinical success.
Data integrity is too often framed as regulatory hygiene, a quality-team concern, a checkbox at submission time. It is enterprise risk that touches asset valuation directly. An inspection finding, an audit observation, or a submission delay can shift due-diligence outcomes, partnership terms, and exit timing. The ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) are the operational floor; the strategic ceiling is asset defensibility.
Sponsors who treat data integrity as commercial-risk-management invest earlier in oversight, ask harder questions of vendors, and build evidence trails that hold up under both regulatory inspection and investor scrutiny. The sponsors who treat it as paperwork tend to find out, late, that the two audiences read the same evidence very differently.
Takeaways
- Data integrity is enterprise risk, not regulatory paperwork.
- Inspectors and investors read the same evidence; only the consequences differ.
- The cost of weak data integrity surfaces late and compounds.
02
Method / How I work
The persuasion sequence
Five steps from regulatory landscape to structured solution.
Every long-form perspective, every keynote, every advisory engagement follows the same logic chain. It is the structure of how I think about clinical systems risk: from regulatory expectation, through assumption and exposure, to consequence and a path forward.
02 · Common assumption
What sponsors typically take for grantedThe phrase: “the danger of that assumption is…”
03 · Risk exposure
What that assumption costsInspection, submission, valuation, partnership terms
04 · Consequence
Where it surfacesLate, expensive, and rarely on the sponsor’s timeline
05 · Structured solution
What to do insteadRisk-based, fit for purpose, sponsor-led
Frame
DiplomaticExposes assumptions, never combative
Read the topics in long form →
Sponsor-led, regulator-credible
More about working with Lauren
Common questions.
Who does Lauren typically work with?+
Lauren’s primary audiences are CEOs, founders, and leadership teams at clinical-stage biotech (typically 2-200 employees, Phase 1-2). Heads of clinical operations, data management, and quality at biotechnology and pharmaceutical sponsors. CTOs and IT leads evaluating clinical systems. Investors conducting due diligence on clinical-stage assets. Engagements range from advisory conversations to structured oversight reviews to inspection-readiness work.
What qualifications and certifications does Lauren hold?+
BSc (Hons) in Medical Microbiology and Immunology from Newcastle University. Cambridge University programme in Communication for Influence and Impact. RQA-certified in Computerised System Validation (Research Quality Association, January 2025). ICH Good Clinical Practice E6 (R2) certified. Chair of the ACDM eDigital Data Management Expert Group, 2019-2024. Co-author of four ACDM industry whitepapers. Ongoing collaborator with the Digital Medicine Society.
What does Lauren NOT advise on?+
Lauren has explicit authority boundaries. Out of scope: AI implementation specifics or technical AI advice; deep IT infrastructure standards; individual vendor critique or named-vendor commentary; medical advice, clinical recommendations, or patient-level guidance; forward-looking statements about specific assets, products, or indications; interpretation of unpublished or confidential clinical data. These boundaries are stated up front so engagements stay defensible.
Where is Lauren based and what regions does she cover?+
Lauren is based in the United Kingdom and works with sponsors globally. The Seuss+ corporate headquarters is in Amsterdam, Netherlands. Lauren’s engagements span European and global sponsor bases, with regulatory framing aligned to ICH GCP E6(R3), EMA guidelines, and FDA 21 CFR Part 11 in parallel rather than in sequence.
What does Lauren mean by “the ecosystem perspective”?+
The ecosystem perspective treats clinical trial data as a single red line through every system, every vendor, and every regulatory checkpoint, rather than as a series of isolated function-by-function handoffs. The industry has become highly sophisticated within individual functions but those functions operate in isolation. The ecosystem view re-anchors clinical trial governance in the sponsor’s responsibility to see the whole picture, define requirements before selecting tools, and demonstrate genuine oversight of every system the data touches.
How does Lauren handle confidentiality with sponsor engagements?+
Sponsor engagements are confidential by default. Public writing and speaking never reference client names or identifiable details unless explicitly approved for public use. Examples used in writing and on stages are generalised structural patterns, not case studies of specific sponsors. This rule is stated in the operating principles and applied without exception.
Get in touch
Podcast, keynote, press interview, or a conversation about clinical systems governance that needs an ecosystem view.
If this resonates, it may be worth reviewing how your current oversight model aligns with evolving regulatory expectations. A short conversation tends to be the cheapest way to find out.